Raymond James Has Bullish Outlook for TSE:MDP Q1 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Raymond James increased their Q1 2026 earnings estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Monday, March 17th. Raymond James analyst M. Freeman now anticipates that the company will post earnings per share of ($0.20) for the quarter, up from their previous forecast of ($0.26). Raymond James currently has a “Strong-Buy” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ FY2026 earnings at ($0.46) EPS.

Several other equities research analysts have also weighed in on the company. Ventum Financial lifted their price objective on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Stifel Canada cut shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of C$5.49.

Medexus Pharmaceuticals Price Performance

TSE:MDP opened at C$2.47 on Wednesday. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56. The business has a fifty day simple moving average of C$3.40 and a two-hundred day simple moving average of C$2.92. The company has a market capitalization of C$55.30 million, a P/E ratio of 11.81 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.